These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 9683452)
21. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Sakata Y; Yamamoto K; Mano T; Nishikawa N; Yoshida J; Hori M; Miwa T; Masuyama T Circulation; 2004 May; 109(17):2143-9. PubMed ID: 15051632 [TBL] [Abstract][Full Text] [Related]
22. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283 [TBL] [Abstract][Full Text] [Related]
23. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Suzuki G; Mishima T; Tanhehco EJ; Sharov VG; Todor A; Rostogi S; Gupta RC; Chaudhry PA; Anagnostopoulos PV; Nass O; Goldstein S; Sabbah HN Br J Pharmacol; 2003 Jan; 138(2):301-9. PubMed ID: 12540520 [TBL] [Abstract][Full Text] [Related]
24. Beneficial effects of therapy on the progression of structural remodeling during healing after reperfused and nonreperfused myocardial infarction: different effects on different parameters. Jugdutt BI; Menon V J Cardiovasc Pharmacol Ther; 2002 Apr; 7(2):95-107. PubMed ID: 12075398 [TBL] [Abstract][Full Text] [Related]
25. ACE inhibition improves cardiac NE uptake and attenuates sympathetic nerve terminal abnormalities in heart failure. Kawai H; Fan TH; Dong E; Siddiqui RA; Yatani A; Stevens SY; Liang CS Am J Physiol; 1999 Oct; 277(4):H1609-17. PubMed ID: 10516201 [TBL] [Abstract][Full Text] [Related]
26. Progression of heart failure: a role for interstitial fibrosis. Sabbah HN; Sharov VG; Lesch M; Goldstein S Mol Cell Biochem; 1995 Jun 7-21; 147(1-2):29-34. PubMed ID: 7494551 [TBL] [Abstract][Full Text] [Related]
27. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. dos Santos L; Salles TA; Arruda-Junior DF; Campos LC; Pereira AC; Barreto AL; Antonio EL; Mansur AJ; Tucci PJ; Krieger JE; Girardi AC Circ Heart Fail; 2013 Sep; 6(5):1029-38. PubMed ID: 23894014 [TBL] [Abstract][Full Text] [Related]
28. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394 [TBL] [Abstract][Full Text] [Related]
29. Effects of left ventricular volume overload on mitochondrial and death-receptor-mediated apoptotic pathways in the transition to heart failure. Moorjani N; Westaby S; Narula J; Catarino PA; Brittin R; Kemp TJ; Narula N; Sugden PH Am J Cardiol; 2009 May; 103(9):1261-8. PubMed ID: 19406269 [TBL] [Abstract][Full Text] [Related]
30. Early administration of Enalapril prevents diastolic dysfunction and ventricular remodeling in rabbits with myocardial infarction. González GE; Wilensky L; Cassaglia P; Morales C; Gelpi RJ Cardiovasc Pathol; 2016; 25(3):208-213. PubMed ID: 26897484 [TBL] [Abstract][Full Text] [Related]
31. Cell death, tissue hypoxia and the progression of heart failure. Sabbah HN; Sharov VG; Goldstein S Heart Fail Rev; 2000 Jun; 5(2):131-8. PubMed ID: 16228140 [TBL] [Abstract][Full Text] [Related]
32. Long-term pharmacological activation of PPARgamma does not prevent left ventricular remodeling in dogs with advanced heart failure. Suzuki G; Khanal S; Rastogi S; Morita H; Mishima T; Anagnostopoulos PV; Nass O; Sharov VG; Tanhehco EJ; Goldstein S; Sabbah HN Cardiovasc Drugs Ther; 2007 Feb; 21(1):29-36. PubMed ID: 17294127 [TBL] [Abstract][Full Text] [Related]
33. Severity of regional myocardial dysfunction is not affected by cardiomyocyte apoptosis in non-ischemic heart failure. Prescimone T; Lionetti V; Caselli C; Aquaro GD; Cabiati M; Ottaviano V; Del Ry S; Giannessi D Pharmacol Res; 2011 Mar; 63(3):207-15. PubMed ID: 20934513 [TBL] [Abstract][Full Text] [Related]
34. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Remme WJ; Riegger G; Hildebrandt P; Komajda M; Jaarsma W; Bobbio M; Soler-Soler J; Scherhag A; Lutiger B; Rydén L Cardiovasc Drugs Ther; 2004 Jan; 18(1):57-66. PubMed ID: 15115904 [TBL] [Abstract][Full Text] [Related]
35. Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction. Connelly KA; Advani A; Advani S; Zhang Y; Thai K; Thomas S; Krum H; Kelly DJ; Gilbert RE Cardiovasc Ther; 2013 Apr; 31(2):84-91. PubMed ID: 21884026 [TBL] [Abstract][Full Text] [Related]
36. Effect of ACE-inhibition on tissue blood flow during acute left ventricular failure in the dog. Hall C; Mørkrid L; Kjekshus J Res Exp Med (Berl); 1987; 187(1):59-70. PubMed ID: 3033782 [TBL] [Abstract][Full Text] [Related]
37. Synergistic interaction between enalapril, L-arginine and tetrahydrobiopterin in smooth muscle cell apoptosis and aortic remodeling induction in SHR. Der Sarkissian S; Marchand EL; Duguay D; deBlois D Br J Pharmacol; 2004 Jul; 142(5):912-8. PubMed ID: 15197102 [TBL] [Abstract][Full Text] [Related]
38. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA; Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927 [TBL] [Abstract][Full Text] [Related]
39. Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload. Ryan TD; Rothstein EC; Aban I; Tallaj JA; Husain A; Lucchesi PA; Dell'Italia LJ J Am Coll Cardiol; 2007 Feb; 49(7):811-21. PubMed ID: 17306712 [TBL] [Abstract][Full Text] [Related]
40. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure. Qiu CB; Qiu CS; Hess P; Clozel JP; Clozel M Acta Pharmacol Sin; 2001 Jun; 22(6):541-8. PubMed ID: 11747762 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]